Inequalities in glycemic and multifactorial cardiovascular control of type 2 diabetes: The Heart Healthy Hoods study.

Aim: This study aimed to analyze glycemic control and multifactorial cardiovascular control targets in people with type 2 diabetes (T2DM) in primary care according to sex and socioeconomic status (SES). Materials and methods: This is an observational, cross-sectional, and multicenter study. We analyzed all the patients with T2DMM aged between 40 and 75 years in Madrid city (113,265) through electronic health records from 01 August 2017 to 31 July 2018. SES was defined by an area-level socioeconomic index stratified by quintiles (1st quintile: more affluent). Outcomes: Outcomes included glycemic control (HbA1c ≤ 7%), 3-factor cardiovascular control [HbA1c ≤ 7%, blood pressure (BP), < 140/90 mmHg, LDL < 100 mg/ml] and 4-factor control [HbA1c ≤ 7%, blood pressure (BP) < 140/90 mmHg, LDL < 100 mg/ml, and BMI < 30 kg/m2]. Multilevel logistic regression models analyzed factors associated with suboptimal glycemic control. Results: In total 43.2% were women. Glycemic control was achieved by 63% of patients (women: 64.2% vs. men: 62.4%). Being more deprived was associated with suboptimal glycemic control (OR: 1.20, 95% CI: 1.10-1.32); however, sex was not related (OR: 0.97, 95% CI: 0.94-1.01). The optimal 3-factor control target was reached by 10.3% of patients (women: 9.3% vs. men: 11.2%), especially those in the 5th quintile of SES. The 4-factor control was achieved by 6.6% of the sample. In the 3-factor control target, being women was related to the suboptimal 3-factor control target (OR: 1.26, 95% CI: 1.19- 1.34) but only belonging to SES 4th quintile was related to the unachieved target (OR: 1.47, 95% CI: 1.04-2.07). Conclusion: Suboptimal glycemic control was associated with being less affluent and suboptimal 3-factor control target was associated with being women.

Mpox (formerly monkeypox) in women: epidemiological features and clinical characteristics of mpox cases in Spain, April to November 2022.

Over 79,000 confirmed cases of mpox were notified worldwide between May and November 2022, most of them in men who have sex with men. Cases in women, for whom mpox might pose different risks, are rare, and Spain has reported more than one third of those in Europe. Using surveillance data, our study found similar time trends, but differences in delay of diagnosis, sexual transmission and signs and symptoms between men and women.

Trends in urinary tract infection hospitalization in older adults in Spain from 2000-2015.

OBJECTIVE: To analyze trends in urinary tract infection hospitalization (cystitis, pyelonephritis, prostatitis and non-specified UTI) among patients over 65 years in Spain from 2000-2015. METHODS: We conducted a retrospective observational study using the Spanish Hospitalization Minimum Data Set (CMBD), with codifications by the International Classification of Diseases (ICD-9). We collected data on sex, age, type of discharge, main diagnosis, comorbid diagnosis, length of stay, and global cost. All the hospitalizations were grouped by age into three categories: 65-74 years old, 75-84 years old, and 85 years old and above. In the descriptive statistical analysis, crude rates were defined as hospitalizations per 1,000 inhabitants aged ≥65. To identify trends over time, we performed a Joinpoint regression. RESULTS: From 2000-2015, we found 387,010 hospitalizations coded as UTIs (54,427 pyelonephritis, 15,869 prostatitis, 2643 cystitis and 314,071 non-specified UTI). The crude rate of hospitalization for UTIs between 2000 and 2015 ranged from 2.09 in 2000 to 4.33 in 2015 Rates of hospitalization were higher in men than in women, except with pyelonephritis. By age group, higher rates were observed in patients aged 85 years or older, barring prostatitis-related hospitalizations. Joinpoint analyses showed an average annual percentage increase (AAPC) in incidence rates of 4.9% (95% CI 3.2;6.1) in UTI hospitalizations. We observed two joinpoints, in 2010 and 2013, that found trends of 5.5% between 2000 and 2010 (95% CI 4.7;6.4), 1.5% between 2010 and 2013 (95% CI -6.0;9.6) and 6.8% between 2013 and 2015 (95% CI -0.3;14.4). CONCLUSIONS: The urinary infection-related hospitalization rate in Spain doubled during the period 2000-2015. The highest hospitalization rates occurred in men, in the ≥85 years old age group, and in non-specified UTIs. There were increases in all types of urinary tract infection, with non-specified UTIs having the greatest growth. Understanding these changing trends can be useful for health planning.

Toenails as a biomarker of exposure to arsenic: A review.

This systematic review summarizes the current evidence related to the reliability of toenail total arsenic concentrations (thereafter "arsenic") as a biomarker of long-term exposure. Specifically, we reviewed literature on consistency of repeated measures over time, association with other biomarkers and metal concentrations, factors influencing concentrations, and associations with health effects. We identified 129 papers containing quantitative original data on arsenic in toenail samples covering populations from 29 different countries. We observed geographic differences in toenail arsenic concentrations, with highest median or mean concentrations in Asian countries. Arsenic-contaminated drinking water, occupational exposure or living in specific industrial areas were associated with an increased toenail arsenic content. The effects of other potential determinants and sources of arsenic exposure including diet, gender and age on the concentrations in toenails need further investigations. Toenail arsenic was correlated with the concentrations in hair and fingernails, and with urine arsenic mainly among highly exposed populations with a toenail mean or median ≥1 µg/g. Overall, there is a growing body of evidence suggesting that arsenic content from a single toenail sample may reflect long-term internal dose-exposure. Toenail arsenic can serve as a reliable measure of toxic inorganic arsenic exposure in chronic disease research, particularly promising for cancer and cardiovascular conditions.

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.

BACKGROUND: Spain is one of the European countries most affected by the COVID-19 pandemic. Serological surveys are a valuable tool to assess the extent of the epidemic, given the existence of asymptomatic cases and little access to diagnostic tests. This nationwide population-based study aims to estimate the seroprevalence of SARS-CoV-2 infection in Spain at national and regional level. METHODS: 35 883 households were selected from municipal rolls using two-stage random sampling stratified by province and municipality size, with all residents invited to participate. From April 27 to May 11, 2020, 61 075 participants (75·1% of all contacted individuals within selected households) answered a questionnaire on history of symptoms compatible with COVID-19 and risk factors, received a point-of-care antibody test, and, if agreed, donated a blood sample for additional testing with a chemiluminescent microparticle immunoassay. Prevalences of IgG antibodies were adjusted using sampling weights and post-stratification to allow for differences in non-response rates based on age group, sex, and census-tract income. Using results for both tests, we calculated a seroprevalence range maximising either specificity (positive for both tests) or sensitivity (positive for either test). FINDINGS: Seroprevalence was 5·0% (95% CI 4·7-5·4) by the point-of-care test and 4·6% (4·3-5·0) by immunoassay, with a specificity-sensitivity range of 3·7% (3·3-4·0; both tests positive) to 6·2% (5·8-6·6; either test positive), with no differences by sex and lower seroprevalence in children younger than 10 years (<3·1% by the point-of-care test). There was substantial geographical variability, with higher prevalence around Madrid (>10%) and lower in coastal areas (<3%). Seroprevalence among 195 participants with positive PCR more than 14 days before the study visit ranged from 87·6% (81·1-92·1; both tests positive) to 91·8% (86·3-95·3; either test positive). In 7273 individuals with anosmia or at least three symptoms, seroprevalence ranged from 15·3% (13·8-16·8) to 19·3% (17·7-21·0). Around a third of seropositive participants were asymptomatic, ranging from 21·9% (19·1-24·9) to 35·8% (33·1-38·5). Only 19·5% (16·3-23·2) of symptomatic participants who were seropositive by both the point-of-care test and immunoassay reported a previous PCR test. INTERPRETATION: The majority of the Spanish population is seronegative to SARS-CoV-2 infection, even in hotspot areas. Most PCR-confirmed cases have detectable antibodies, but a substantial proportion of people with symptoms compatible with COVID-19 did not have a PCR test and at least a third of infections determined by serology were asymptomatic. These results emphasise the need for maintaining public health measures to avoid a new epidemic wave. FUNDING: Spanish Ministry of Health, Institute of Health Carlos III, and Spanish National Health System.

Determinantes de la vacunación de la gripe en personas de más de 65 años: 20 años no es nada / Determinants of influenza vaccination in people over 65 years: 20 years is nothing

Fundamentos: La efectividad de la vacuna de la gripe ha hecho que sea una medida recomendada para personas de alto riesgo, entre ellos los adultos de 65 y más años. En este trabajo se planteó analizar la evolución de las tasas anuales de vacunación, e identificar subgrupos en la población que tuviese un riesgo significativo de no vacunarse. Métodos: Para el primer objetivo, la fuente de información fueron los datos que informa el Ministerio de Sanidad, Consumo y Bienestar Social. Para analizar las tendencias se llevó a cabo un análisis de series temporales interrumpidas. La fuentede información para el segundo objetivo fue la Encuesta Nacional de Salud de España de 2017. Se llevó a cabo un análisis de regresión logística multivariable. Resultados: La tasa de vacunación de la gripe mostró desde latemporada 2006-07 una disminución absoluta anual de 1,2 puntos (95% IC: 0,8%, 1,6%). La prevalencia de vacunación en 2017 era de 54,9%. Las variables independientemente asociadas con la mayor vacunación de la gripe eran ser hombre, la mayor edad, haber nacido en España, tener más visitas al médico, tener una prescripción de medicamentos, tener una enfermedad crónica, no ser fumador, y el menor consumo de frutas. Conclusiones: La cobertura de la vacuna de la gripe en población de 65 y más años no solo está por debajo de lo recomendado por la Organización Mundial de la Salud e indicado por el Consejo Interterritorial del Sistema Nacional de Salud sino que está disminuyendo significativamente cada año. Los subgrupos con menores tasas de vacunación (mujeres, menores de 75 años, no nacidos en España, con menos visitas al médico,sin prescripción de medicamentos, sin enfermedades crónicas, fumadores y con más consumo de frutas) deben ser identificados para desarrollar campañas y programas destinados a incrementar su vacunación de la gripe de forma que pueda aportar todo su beneficio potencial a la población específica

Background: The effectiveness of the influenza vaccine has made it a recommended intervention for people at high risk, including adults over 65. This work aimed to analyse the trends of annual vaccination rates, and identify subgroups in the population that have a significant risk of not receiving the vaccine. Methods: For the first objective, the source of information was the data reported by the Ministry of Health. To determine the trends in vaccination an analysis of interrupted time series was conducted. A multivariable logistic regression analysis was carried out with the National Health Survey (ENSE) of 2017 for the second objective. Results: The rate of influenza vaccination showed an absolute annual decrease of 1,2 points since the 2006-07 season (95% CI: 0,8%, 1,6%). The prevalence of vaccination in 2017 was 54,9%. The variables independently associated with a higher probability of the influenza vaccine were males, older age, born in Spain, having more visits to the doctor, with prescription of medications, having a chronic illness, being non-smoker, and the lower consumption of fruits. Conclusions: The coverage of the flu vaccine in the population aged 65 and over is not only below the recommendation of the World Health Organization and indicated by the Interterritorial Council of the National Health System, but is significantly decreasing every year. Sub-groups with lover vaccination rates (women, younger than 75 years , foreign born, with less visits to primary care, no prescription of medicines, no chronic diseases, smokers and with higher intake of fruit) should be targets to develop campaigns and programs to increase their uptake of influenza vaccination so it could provide its potential population benefit